Home › Compare › EPRSQ vs EQR

EPRSQ vs EQR: Dividend Comparison 2026

EPRSQ yields 200000000.00% · EQR yields 5.87%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EPRSQ wins by $4.875657285131069e+59M in total portfolio value
10 years
EPRSQ
EPRSQ
● Live price
200000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.875657285131069e+59M
Annual income
$487,565,248,955,786,300,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00
Full EPRSQ calculator →
EQR
EQR
● Live price
5.87%
Share price
$59.15
Annual div
$3.47
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.8K
Annual income
$5,475.61
Full EQR calculator →

Portfolio growth — EPRSQ vs EQR

📍 EPRSQ pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEPRSQEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EPRSQ + EQR cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
EPRSQ pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EPRSQ
Annual income on $10K today (after 15% tax)
$17,000,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$414,430,461,612,418,300,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00/yr
EQR
Annual income on $10K today (after 15% tax)
$499.01/yr
After 10yr DRIP, annual income (after tax)
$4,654.27/yr
At 15% tax rate, EPRSQ beats the other by $414,430,461,612,418,300,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EPRSQ + EQR for your $10,000?

EPRSQ: 50%EQR: 50%
100% EQR50/50100% EPRSQ
Portfolio after 10yr
$2.4378286425655345e+59M
Annual income
$243,782,624,477,893,130,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00/yr
Blended yield
100.00%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

EPRSQ
No analyst data
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+18.9% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EPRSQ buys
0
EQR buys
0
No recent congressional trades found for EPRSQ or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEPRSQEQR
Forward yield200000000.00% ✓5.87%
Annual dividend / share$2.00$3.47 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8% ✓
Portfolio after 10y$4.875657285131069e+59M$47.8K ✓
Annual income after 10y$487,565,248,955,786,300,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00 ✓$5,475.61
Total dividends collected$4.875656971401711e+59M$23.0K ✓
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: EPRSQ vs EQR ($10,000, DRIP)

YearEPRSQ PortfolioEPRSQ Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$20,000,010,700$20,000,000,000.00$11,380$679.82+$20000.00M → EPRSQ
2$37,383,218,970,104,910$37,383,197,570,093,464.00$13,014$837.25+$37383218970.09M → EPRSQ
3$65,303,942,472,059,150,000,000$65,303,902,472,014,860,000,000.00$14,961$1,036.20+$65303942472059152.00M → EPRSQ
4$106,615,009,060,306,890,000,000,000,000$106,614,939,185,088,440,000,000,000,000.00$17,297$1,289.22+$1.0661500906030689e+23M → EPRSQ
5$162,672,273,967,082,950,000,000,000,000,000,000$162,672,159,889,023,270,000,000,000,000,000,000.00$20,121$1,613.15+$1.6267227396708296e+29M → EPRSQ
6$231,966,340,306,755,300,000,000,000,000,000,000,000,000$231,966,166,247,422,140,000,000,000,000,000,000,000,000.00$23,561$2,030.84+$2.319663403067553e+35M → EPRSQ
7$309,138,182,305,146,600,000,000,000,000,000,000,000,000,000,000$309,137,934,101,162,400,000,000,000,000,000,000,000,000,000,000.00$27,783$2,573.54+$3.091381823051466e+41M → EPRSQ
8$385,031,777,252,258,400,000,000,000,000,000,000,000,000,000,000,000,000$385,031,446,474,403,340,000,000,000,000,000,000,000,000,000,000,000,000.00$33,013$3,284.39+$3.850317772522584e+47M → EPRSQ
9$448,184,411,799,345,900,000,000,000,000,000,000,000,000,000,000,000,000,000,000$448,183,999,815,344,300,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00$39,547$4,223.51+$4.481844117993459e+53M → EPRSQ
10$487,565,728,513,106,900,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000$487,565,248,955,786,300,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00$47,791$5,475.61+$4.875657285131069e+59M → EPRSQ

EPRSQ vs EQR: Complete Analysis 2026

EPRSQ — Stock

EPIRUS Biopharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and commercializes biosimilar therapeutics worldwide. Its lead product candidate is BOW015, a biosimilar version of Remicade (infliximab) for the treatment of various inflammatory diseases. The company's pipeline of biosimilar product candidates also include BOW050, a biosimilar version of Humira (adalimumab) to treat inflammatory diseases, including rheumatoid arthritis and various other forms of adult and pediatric arthritis, ankylosing spondylitis, inflammatory bowel disease, and chronic psoriasis and psoriasis; and BOW070, a biosimilar version of Actemra (tocilizumab) for the treatment of rheumatoid arthritis, polyarticular arthritis, and systemic juvenile idiopathic arthritis. In addition, it is developing BOW080, a biosimilar version of Soliris for the treatment of ultra-rare blood disorders, including paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and BOW100, a biosimilar version of SIMPONI for the treatment of inflammatory diseases, including rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, and psoriatic arthritis. The company has a license agreement with Sun Pharmaceutical Industries Ltd.; license and collaboration agreement with Livzon Mabpharm Inc.; and collaboration agreement with Polpharma S.A. The company was founded in 2011 and is headquartered in Boston, Massachusetts. On July 25, 2016, Epirus Biopharmaceuticals, Inc. filed a voluntary petition for liquidation under Chapter 7 in the US Bankruptcy Court for the District of Massachusetts.

Full EPRSQ Calculator →

EQR — REIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this EPRSQ vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EPRSQ vs SCHDEPRSQ vs JEPIEPRSQ vs OEPRSQ vs KOEPRSQ vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.